Has Bashar Hannawi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,429 in general payments to Bashar Hannawi, MD across 39 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bashar Hannawi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bashar Hannawi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bashar Hannawi, MD

Cardiovascular Disease · Detroit, MINPI 1629332069

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,929 of the $2,429 with a category attached, or 79.4%. 13 manufacturers reported payments, led by Abbott at 53.9% of the total. Reporting peaked in 2019 at $1,202 and has fallen 79.0% since, to $253 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in MI, where the typical reported total is $2,775.

$2,429in general payments, 2019–2025

Across 39 payments — averaging $62.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$1K
Boston Scientific$540
E.r. Squibb & Sons, L.L.C.$217
Procyrion, Inc.$129
Medtronic$42
Johnson & Johnson$35
plus $158 from 7 others

$21,413in research payments, 2019–2025

Across 6 payments — averaging $3568.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$21K

What the payments were for

Grants$50021%
Food & beverage$1,92979%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	16	$1,309
Boston Scientific	3	$540
E.r. Squibb & Sons, L.L.C.	3	$217
Procyrion, Inc.	3	$129
Medtronic(2 entities)	3	$42
Johnson & Johnson	2	$35
Amgen	2	$32
Actelion Pharmaceuticals US, Inc.	2	$28
Kestra Medical Technology Services, Inc.	1	$27
Astellas Pharma US Inc	1	$21
Novo Nordisk	1	$18
Getinge USA Sales, LLC	1	$17
United Therapeutics Corporation	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

GENERAL - STRUCTURAL HEART$500
THORATEC HEARTMATE 3 LVAS IMPLANT KIT$446
CardioMEMS HF System$342
HeartMate 3 Left Ventricular Assist Device$179
HeartMate 3 Left Ventricular Dev$138
CAMZYOS$125

How this compares

$2,429 in reported general payments places this provider in the 45th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan →

Medicare billing

Part B allowed, 2024

$30,584

Medicare patients

Services billed

327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VyndamaxTafamidis	19	$430,312
VyndaqelTafamidis Meglumine	11	$235,981
EntrestoSacubitril/Valsartan	127	$135,393
JardianceEmpagliflozin	110	$123,468
EliquisApixaban	104	$98,254
FarxigaDapagliflozin Propanediol	63	$56,159
PrografTacrolimus	12	$20,158
Tacrolimus	91	$17,264
Sildenafil Citrate	25	$9,846
Potassium Chloride	97	$5,144
Amiodarone Hcl	51	$4,120
Bumetanide	105	$3,627
Mycophenolate Mofetil	53	$3,498
Sirolimus	19	$2,780
Metoprolol Succinate	118	$2,272

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Detroit

Pedro Villablanca SpinettoDetroit$620K
Wayne WeaverDetroit$340K
Brian OneillDetroit$250K
Karthikeyan AnanthasubramaniamDetroit$112K
Gerald KoenigDetroit$96K
David LanfearDetroit$82K
Celeste WilliamsDetroit$70K
Mahir ElderDetroit$68K
Cori RussellDetroit$67K
Pedro Engel GonzalezDetroit$66K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →